Follow-up Data Confirms That Inclisiran Provides Long-Term Reduction of LDL-Cholesterol

February 21st, 2024|Categories: Perspectives on Current Science|

Cardiovascular disease is the leading cause of death in the United States, exceeding all types of cancer, unintentional injury, and stroke combined. However, updated data from Novartis's open-label trial shows promising long-term results for inclisiran (Leqvio), the first and only small interfering RNA (siRNA) ...

Base Editing in Clinical Trials to Treat Acute Lymphoblastic Leukemia

January 23rd, 2024|Categories: Perspectives on Current Science|

Base editing has experienced a rapid rise in use since it first came on the scene in 2016, with multiple trials underway, testing its ability to treat conditions with precise, single-letter changes to DNA. The technique presents a potentially more accurate and safer method ...

Go to Top